Trogenix Ltd, a Scottish BioTech company dedicated to innovative cancer therapies, announced the completion of its Series A financing, raising €80 million, to advance its pipeline of potentially curative cancer therapies across multiple aggressive solid tumours.
The Series A financing was led by IQ Capital with participation from founding investor 4BIO Capital, returning investors Cancer Research Horizons, the Brain Tumor Investment Fund, and new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital, as well as undisclosed private investors.
Ken Macnamara, Chief Executive Officer at Trogenix, said: “This significant investment accelerates our lead programme in glioblastoma and follow-on programme in colorectal cancer liver metastases through the clinic, advances our pipeline in liver and lung cancers, and further enhances our Odysseus platform. We are honoured to have the support of existing and new investors who share our mission to deliver breakthrough treatments and pursue cures for the thousands of patients and families facing devastating diagnoses each year.”
In 2025, European BioTech funding has remained robust, with capital concentrating around high-potential therapeutic platforms. Trogenix’s Series A places it among the continent’s largest early-stage rounds this year, alongside this morning’s Nanophoria’s €83.5 million Series A in Italy, CHARM Therapeutics’ €68.5 million Series B, and NUCLIDIUM’s €84 million Series B.
The scale of these transactions reflects continued investor commitment to European BioTech innovation, particularly where platform technologies promise both scientific and commercial scalability.
Within the UK, oncology-focused ventures such as LIfT BioSciences (€12 million), Cyted Health (over €37 million), and Enhanced Genomics (€16 million) continue to attract substantial backing. Against this backdrop, Trogenix’s round not only stands out for its size but also aligns with a broader European trend favouring precision oncology and advanced gene-based therapeutics transitioning toward clinical development.
Max Bautin, Co-founder and Managing Partner at lead investor, IQ Capital, said: “Our outsised investment in Trogenix in today’s selective funding landscape reflects our confidence in the company’s world-leading science, exceptional management team and a clear roadmap for delivery both in the clinic and commercially. We are particularly excited by the potential opportunities ahead across Trogenix’s pipeline and look forward to our future collaboration.”
Trogenix was created in 2023 based on Co-founder Professor Steve Pollard’s research at the University of Edinburgh – including its UK Centre for Mammalian Synthetic Biology and Institute for Regeneration and Repair – and the Cancer Research UK Scotland Centre.
Using proven AAV vectors, their proprietary Synthetic Super-Enhancers (SSEs) are delivered directly to tumour cells without detection. Their SSEs enable precision in gene control, effectively revealing cancer to the body’s immune system and killing tumour cells. For any cells escaping Trogenix’s technology, their ‘Trojan horse’ can counter recurrence, offering potentially curative ‘one-and-done’ treatments for aggressive tumours.
Iain Foulkes, Chief Executive Officer at Cancer Research Horizons, commented: “Trogenix’s platform technology is a powerful example of the innovation we seek to accelerate. Representing our largest investment to date, this partnership reflects our commitment to advancing science with the potential to transform cancer treatment. As they advance into clinical trials for glioblastoma, one of the hardest to treat cancers, we’re pleased to support a team whose work could reshape therapeutic approaches and improve outcomes for patients facing the greatest need.”
The investment underscores the curative potential of Trogenix’s precision genetic medicines driven by the Company’s Odysseus platform that identifies and targets the universal vulnerabilities of solid tumours. Trogenix’s technology delivers highly potent combination payloads that kill cancerous cells and stimulate the immune system whilst leaving surrounding healthy tissue untouched, thereby changing the treatment paradigm for cancer patients.
This investment in Trogenix also represents Cancer Research Horizons’ largest investment to-date.
Dima Kuzmin, Co-founder and Managing Partner at founding investor, 4BIO Capital, and Chairman of Trogenix, added: “We are proud to have supported Trogenix through the initial incubation stage and spin-out from the University of Edinburgh, and are very happy to continue our support alongside this strong syndicate. It is exciting to see the company forge ahead with its clinical development to deliver a pioneering portfolio of cancer therapies to patients in need.”
Trogenix’s lead programme, in glioblastoma (GBM), one of the most aggressive and treatment-resistant brain cancers, is advancing toward clinical trials with first patient dosing anticipated in Q1 2026. Only 25% of GBM patients survive beyond one year and despite decades of research and significant investment, the company says treatment options remain severely limited. The Company’s follow-on programme is in colorectal cancer liver metastases (CRCLM). Colorectal cancer is the third most common cancer worldwide, with at least 25% of patients developing CRCLM.
In addition to its lead and follow-on programmes, Trogenix will be developing its pipeline focused on other aggressive solid cancers including hepatocellular carcinoma and non-small cell lung carcinoma.
Read the orginal article: https://www.eu-startups.com/2025/10/edinburgh-based-biotech-trogenix-lands-e80-million-to-accelerate-curative-cancer-treatments/
